A perioperative study associated earlier midazolam administration with a different stress-biomarker pattern.
One hundred twenty adults were allocated to two groups matched for age and sex. Salivary alpha-amylase was measured at sequential perioperative points. One group received midazolam before spinal anesthesia and the other afterward. The earlier-treatment group showed lower levels at the relevant procedural assessments.
A biomarker difference is not a direct measurement of subjective distress, memory, pain, or clinical outcome. The groups experienced different drug exposure at the sampling times. Matching selected characteristics does not eliminate all differences or prove that the biomarker uniquely reflects anxiety.
An expert should identify both the sampling clock and treatment clock. This paper cannot establish how much anxiety an individual experienced from a salivary value alone. It illustrates why treatment timing can shape a physiological measurement without making that measurement a validated forensic test of a person’s mental state.
Source reviewed: Evaluation of Salivary Alpha Amylase Levels for Determining Stress Variations in Patients Undergoing (PMC8633698). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Shared Midazolam Premedication in a Pediatric Caudal-Anesthesia Trial; Multimedia Bronchoscopy Information Reduced Midazolam Requirements in a Randomized Study.